The only word that continues to come to my mind is "odd". With JPS "deciding" to move on and the rehash of previously presented material as you pointed out, it appears this company is lost and investors may start to walk away......
Perhaps if and when the FDA clinical hold on 184 and 320 are released, more clarity will be provided by the IDIX executive team.
Thank you for your continued updates and comments, I sincerely appreciate them.
>>The most interesting part of the webcast was the discussion at the end by the practicing hepatologist; however, this material has more relevance to VRTX and MRK than it does to IDIX.<<
Translation? Because they have the protease inhibitors which are going to be the "newest" drug tools to fight HepC? Because they can appreciate the evolution of HepC treatment and have a better understanding of what IDIX's pipeline is really worth ie one of them may want to buy out IDIX???
Market Data 
Markets 
AI
